Patents Examined by George W Kosturko
  • Patent number: 11400100
    Abstract: The present invention relates to an ophthalmic composition comprising from 0.005% to 0.02% bimatoprost by weight and one or more pharmaceutically acceptable excipient, wherein said composition is free of benzalkonium chloride. The invention also relates to bimatoprost ophthalmic compositions comprising one or more penetration enhancers other than benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and their use for lowering intraocular pressure and treating glaucoma.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: August 2, 2022
    Assignee: Somerset Therapeutics, LLC.
    Inventors: Mandar V Shah, Veerappan Subramanian, Ilango Subramanian, Aman Trehan
  • Patent number: 11400067
    Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 2, 2022
    Assignee: INTRABIO LIMITED
    Inventor: Michael Strupp
  • Patent number: 11389427
    Abstract: A method of treating cardiac hypertrophy and/or heart failure in a subject includes administering to the subject a therapeutically effective amount of a REV-ERB? agonist.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: July 19, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Lilei Zhang, Mukesh K. Jain, Thomas Burris
  • Patent number: 11384098
    Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 12, 2022
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 11376252
    Abstract: A method for preventing, treating and/or improving a prostatic disease or disorder associated with epithelial hyperplasia and/or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need thereof, wherein the multikinase inhibitor has a certain spectrum of kinase inhibitory activity. The multikinase inhibitor is sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and/or lenvatinib. The prostatic disease or disorder is selected from the group consisting of benign prostate hyperplasia and its associated lower urinary tract symptoms, fibrosis of ureters and renal pelvis, prostate adenoma, and prostatic intraepithelial neoplasia in animals and humans.
    Type: Grant
    Filed: December 30, 2017
    Date of Patent: July 5, 2022
    Assignee: AIVIVA BIOPHARMA, INC.
    Inventors: Diane Dan-shya Tang-Liu, Tiffany Constance Liu, Gerald Woodrow Devries
  • Patent number: 11372003
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 28, 2022
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Patent number: 11369605
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 28, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • Patent number: 11365188
    Abstract: Janus kinases (JAKs) inhibitors have the following Formula (I):
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: June 21, 2022
    Inventor: Xibin Liao
  • Patent number: 11364237
    Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 21, 2022
    Assignee: ONCOCROSS CO., LTD.
    Inventor: Yi-Rang Kim
  • Patent number: 11351165
    Abstract: It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 7, 2022
    Assignee: LDN Pharma Limited
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11337969
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 24, 2022
    Assignee: X4 Pharmaceuticals, Inc.
    Inventor: Robert D. Arbeit
  • Patent number: 11318136
    Abstract: Compositions for inhibiting the aggregation of a granin from a non-toxic low molecular weight form to a toxic high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form are provided. Such a composition typically includes one or more active compounds or agents, which may also be referred to herein as disaggregation compounds. Using the compounds and compositions described herein, methods of i) modulating, inhibiting or preventing the interaction of granins with metal ions, ii) modulating, inhibiting, preventing the aggregation of granins or dissociating aggregated granins, iii) reducing or inhibiting cell toxicity, iv) treating or preventing dementia or Alzheimer's disease, and v) preventing or treating Parkinson's and/or Huntington's diseases are also provided.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 3, 2022
    Inventor: Seung Hyun Yoo
  • Patent number: 11311518
    Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 26, 2022
    Assignee: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
  • Patent number: 11304943
    Abstract: The invention is based on the finding that co-administration of 6-?-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-?-naltrexol with vitamin D results in a greater decrease in the growth of cancer cells compared to the sum of the effects of each agent when administered in isolation.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 19, 2022
    Assignee: LDN PHARMA LIMITED
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11304962
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 19, 2022
    Assignee: COVIS PHARMA GMBH
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Patent number: 11298329
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 12, 2022
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 11285145
    Abstract: Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant. Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: March 29, 2022
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Hazel Hunt, Joseph Custodio
  • Patent number: 11278546
    Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 22, 2022
    Assignee: AIVIVA BIOPHARMA, INC.
    Inventors: Diane Tang-Liu, Gerald Woodrow Devries, Tiffany Constance Liu
  • Patent number: 11278524
    Abstract: The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignee: STEMIRNA (SHANGHAI) BIOTECHNOLOGY CO. LTED.
    Inventors: Dean G. Tang, Xin Chen
  • Patent number: 11273157
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 15, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia